A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors

Aurelius Gabriel Omlin, James F. Spicer, Debashis Sarker, David James Pinato, Roshan Agarwal, Philippe Alexandre Cassier, Chara Stavraka, Monsterrat Blanco, Aneta Suder, Suzanne Allan, Simon Heaton, Shaun Decordova, Lorna Pope, Jenny Prince, Kohei Noguchi, Keith Jones, Michiyasu Inatani, Rie Shiokawa, Udai Banerji, Sarah Patricia Blagden

Research output: Chapter in Book/Report/Conference proceedingMeeting abstractpeer-review

Original languageEnglish
Title of host publicationJournal of Clinical Oncology
Number of pages1
Publication statusPublished - 20 May 2012
Event48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, Israel
Duration: 1 Jun 20126 Jun 2012


Conference48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Cite this